https://www.arsenalbio.com | United States | 2018 | $305M
ArsenalBio is a clinical-stage programmable cell therapy company based in the United States that is focused on developing advanced CAR T-cell therapies for solid tumors. The company has raised a $220 million Series B financing round from a diverse group of investors, including SoftBank Vision Fund 2 and Bristol-Myers Squibb. ArsenalBio is led by founder and CEO Ken Drazan, M.D., and is integrating technologies like CRISPR, synthetic biology, and machine learning to create a new paradigm for discovering and developing effective and accessible immune cell therapies. The company’s goal is to impact outcomes for a broader number of cancer patients, particularly those with solid tumors, which have proven more challenging for traditional CAR T-cell therapies.
